Alzheimer’s Disease Therapeutics And Diagnostics Market To Reach $11.5bn In 2020, A New Visiongain Study Predicts

06 September 2018
Pharma

A new report by visiongain forecasts the overall world market for Alzheimer’s disease therapeutics and diagnostics will reach $11.5bn in 2020. That revenue prediction and others appear in Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast 2016-2026: Opportunities for Leading Companies, published in May 2016. Visiongain is a business information publisher and consultancy in London, UK. It produces research, data and analysis to help organisations understand markets and their potentials.

This study also analyses qualitative issues affecting the Alzheimer’s disease therapeutics and diagnostics drug market from 2015, with recent events, opinions and predictions. Economic impact, clinical trial guidelines, new research development, and many other forces are discussed. The result is a quantitative and qualitative analysis of the Alzheimer’s disease therapeutics and diagnostics market, showing commercial potentials of those drugs and diagnostics from 2016 to 2026.

From 2015, new therapies and high medical needs encourage investments, developments, wider treatment and higher sales from upcoming drugs. The new study discusses commercial potentials of top leading pipeline drugs and diagnostics tests. That investigation gives multilevel revenue forecasting to 2026. Shruti Tayal, a pharmaceutical industry analyst in visiongain, said: “The Alzheimer’s disease therapeutics market has been stagnant over the last few years, with major disappointments in late stage clinical trials. However, at present there are many drugs in Phase III trial, hoping for approval. There is a more positive outlook in the diagnostics market with advances in blood-based biomarkers, they are making a huge impact on clinical research of Alzheimer’s drug candidates. There is an increasing drive towards finding the underlying cause of Alzheimer’s disease to develop a drug which can change the course of history. Since the older population is increasing in the world, the cost incurred by treatment and care for Alzheimer’s has become a global burden.” The fastest growth will continue to be seen in the emerging economies, where there is still high growth in revenues of Alzheimer’s drugs that have gone off-patent in the majority of developed markets. Many leading Alzheimer’s therapeutic companies are investing aggressively to increase their presence in the country and this trend is set to continue with the demand from a rapidly ageing population.

That updated investigation shows revenue forecasts to 2026 at overall world market, submarket, product and national level. It has two submarkets:

• Alzheimer’s drug market • Alzheimer’s diagnostics market

Those analyses forecast the revenues of 6 leading Alzheimer’s drugs in the market and in the pipeline from 2016 to 2026, which are Namenda, Aricept, Exelon, Solanezumab, Gantenerumab and MK-8931. The new survey also discusses Alzheimer’s drug candidates in clinical trials, examining research and development. The market is expected to grow in the second half of the forecast period.

That report includes trends and forecast revenues in leading national markets. Countries and regions analysed are the US, the EU (Germany, France, the UK, Spain, Italy), Japan, BRIC (Brazil, Russia, India and China) and the Rest of the World (RoW). That study also contains three interviews with other authorities on Alzheimer’s disease.

Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast 2016-2026 : Opportunities for Leading Companies adds to visiongain’s reports on industries and markets in healthcare. Those studies analyse pharmaceuticals, medical devices, diagnostics and contract services, showing their technological, clinical and commercial potentials.

Recent News

Visiongain Publishes Single-Cell Analysis Market Report 2022-2032

The global single cell analysis market was valued at US$3,255.0 million in 2022 and is projected to grow at a CAGR of 15.1% during the forecast period 2022-2032.

26 May 2022

Read

Visiongain Publishes Ophthalmic Devices Market Report 2022-2032

The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.

19 April 2022

Read

Visiongain Publishes Vaccine Contract Manufacturing Market Report 2022-2032

The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet

13 April 2022

Read

Visiongain Publishes Pharmaceutical Contract Manufacturing Market Report 2022-2032

The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.

13 April 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever